Mural Oncology PLC (NASDAQ:MURA) Receives Average Rating of “Hold” from Analysts

Shares of Mural Oncology PLC (NASDAQ:MURA) have been given an average rating of “Hold” by the five research firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $12.00.

A number of brokerages have issued reports on MURA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mural Oncology in a research report on Wednesday. Wall Street Zen downgraded shares of Mural Oncology from a “hold” rating to a “strong sell” rating in a report on Sunday, August 10th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Emerald Mutual Fund Advisers Trust bought a new position in shares of Mural Oncology during the second quarter valued at $192,000. Armistice Capital LLC increased its holdings in shares of Mural Oncology by 1.3% during the first quarter. Armistice Capital LLC now owns 1,722,000 shares of the company’s stock worth $2,170,000 after buying an additional 22,000 shares in the last quarter. Soleus Capital Management L.P. bought a new position in shares of Mural Oncology in the second quarter valued at approximately $3,270,000. F m Investments LLC acquired a new position in shares of Mural Oncology in the 2nd quarter worth approximately $192,000. Finally, Diametric Capital LP bought a new stake in Mural Oncology during the 2nd quarter worth approximately $864,000. Institutional investors own 80.21% of the company’s stock.

Mural Oncology Stock Performance

Mural Oncology stock opened at $2.03 on Friday. The firm has a market capitalization of $35.11 million, a price-to-earnings ratio of -0.29 and a beta of 2.93. Mural Oncology has a 52 week low of $0.95 and a 52 week high of $4.74. The company has a 50 day moving average price of $2.08 and a 200 day moving average price of $2.24.

Mural Oncology (NASDAQ:MURA) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.38. Equities analysts forecast that Mural Oncology will post -7.54 earnings per share for the current fiscal year.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.